Program
VTRU200
A development code.
Its studies are mostly in Leukemia, Myeloid, Acute, led by Vitruviae.
Furthest: phase 2, since Jul 29, 20261 company-led study, 1 open or runningNext primary completion: Jan 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Vitruviae | 11 open or running | phase 2since Jul 29, 2026 | Jul 29, 2026 | Jan 2028phase 2 · NCT07749976 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 29, 2026First study: phase 2 study in Leukemia, Myeloid, AcuteFirst studyNCT07749976 · 108 planned
Ahead
- Jan 2028Primary completion: phase 2 study in Leukemia, Myeloid, AcuteNCT07749976
TargetBeta
CD3E →read by rule
“VTRU200 is an investigational trispecific T-cell engager that binds stress-associated glycans, phosphatidylserine, and CD3 to redirect T cells toward cancer cells.”study text, by rule · the study
Other programs on CD3E
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| etentamig | AbbVie | phase 3 | 11 |
| obrixtamig | Boehringer Ingelheim | phase 3 | 11 |
| surovatamig | AstraZeneca | phase 3 | 10 |
| Anti-CD19/CD3 Bispecific Antibody MK-1045 | Merck | phase 3 | 8 |
| cevostamab | Hoffmann-La Roche | phase 3 | 8 |
| ramantamig | Johnson & Johnson | phase 3 | 7 |
| pasritamig | Johnson & Johnson | phase 3 | 5 |
| TQB2825 | Sino Biopharmaceutical | phase 3 | 5 |
| Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934 | Sino Biopharmaceutical | phase 3 | 4 |
| gocatamig | Merck | phase 3 | 4 |
| Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001 | AbbVie | phase 2 | 2 |
| Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492 | AstraZeneca | phase 2 | 2 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07749976Leukemia, Myeloid, Acute | 2 | Not yet recruiting | Jan 2028 | 108 |
How it is read
Names in the registry
- “VTRU200”, 1 entry
Codes read as this program: VTRU200.
Conditions, from the studies’ own filings
- Leukemia, Myeloid, Acute, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.